Flexible and intuitive operation of a wide range of biological processes with the SciVario® twin bioreactor control system.
List view / Grid view
Filter the results
Researchers have developed a way to produce proteins from lettuce which can effectively combat pulmonary arterial hypertension in animals.
Drug Target Review explores the latest applications of stem cells in modelling disease, drug production and the most recent steps in regenerative medicine provided by research.
The G-protein coupled receptor Frizzled, implicated in diseases like cancer, can be targeted with small molecules which could provide the basis for anti-cancer therapeutics, according to researchers.
Scientists have discovered that a plant-based compound called halofuginone activates a pathway that results in better antibodies and could improve the effectiveness of vaccines.
A study has revealed an enzyme in bacteria that produces a molecule which is toxic to other bacteria and shows promise as an antibiotic substitute.
A new process for identifying and biosynthesising drug candidates has been discovered by researchers at the Carl R Woese Institute for Genomic Biology.
A team has discovered that fungi use the Diels-Alder reaction to assemble new compounds that have potential pharmaceutical uses.
Protein therapeutics are a major class of biopharmaceuticals and monoclonal antibodies (mAbs) rule this domain. In this article, Dr Nancy Lopez-Anton outlines the key technologies employed in this important therapeutic discovery area; how they have evolved and what obstacles must be navigated to ensure future success.
Monoclonal antibodies are used in a wide range of applications, such as basic research, biopharmaceutical development and in vitro diagnostics.
In a recent study in mice, researchers have found a way to deliver specific drugs to parts of the body that are exceptionally difficult to access.
Target-driven drug discovery, in which the starting point is a specific protein target hypothesised to play an important role in disease, has been the dominant paradigm for the last few decades. However, phenotypic-driven drug discovery, which does not rely on a specific target hypothesis, is starting to regain traction for…
Sartorius Stedim Biotech introduces BIOSTAT® RM TX with Flexsafe® RM TX for producing consistent quality cellular products
Sartorius Stedim Biotech (SSB), a leading international supplier for the biopharmaceutical industry announced the launch of the BIOSTAT® RM TX single-use bioreactor, a new wave mixed system developed specifically for closed, automated expansion of consistent quality cell products such as ex vivo cellular immunotherapies...